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Abstract 57 
Graft versus host disease (GVHD) is a major complication of haematopoietic stem cell 58 
transplantation (HSCT). A number of inflammatory cytokines/chemokines are implicated in 59 
GVHD and have been identified in numerous single centre studies as potential biomarkers for 60 
acute and/or chronic GVHD. In this study we analysed candidate inflammatory biomarkers 61 
(BAFF, interleukin 33 (IL-33), CXCL10 and CXCL11) in a two centre study. Biomarkers were 62 
evaluated pre-transplant and at serial time-points post-transplant in acute and chronic GVHD 63 
patient sera with time-matched control samples from patients without GVHD. Further validation 64 
was performed using the human skin explant assay, clinical GVHD biopsies and mRNA 65 
expression analysis. 66 
 BAFF was significantly increased pre-transplant. BAFF, IL-33, CXCL10 and CXCL11 showed 67 
increased levels in acute GVHD patient sera and high protein expression in grades II-III of the in 68 
vitro skin explant graft versus host reaction (GVHR) group. BAFF, CXCL10 and CXCL11 also 69 
showed increased mRNA expression levels in clinical biopsies compared to the no/low grade 70 
GVHD group. BAFF, CXCL10 and CXCL11 levels were increased in chronic GVHD patient 71 
sera.  The results identify BAFF and CXCL10 as predictive biomarkers for acute GVHD and 72 
BAFF, CXCL10 and CXCL11 as useful diagnostic biomarkers for acute GVHD and chronic 73 
GVHD.  74 
 75 
 76 
 77 
 78 
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Introduction 79 
Haematopoietic stem cell transplantation (HSCT) is increasingly used to treat patients suffering 80 
from malignant and non-malignant haematopoietic disorders. A frequent and potentially life 81 
threatening complication is graft-versus-host disease (GVHD) whereby donor T-cells attack host 82 
target organs causing substantial damage and apoptosis of cells giving rise to clinical symptoms 83 
of acute GVHD (aGVHD) followed by chronic GVHD (cGVHD). Severity of aGVHD is graded 84 
according to the number of organs involved and the severity of organ dysfunction (1) and occurs 85 
shortly after transplant whereas cGVHD either overlaps with aGVHD or is more delayed (after 86 
100 days). The aGVHD process largely involves apoptosis and necrosis (2) with cGVHD having 87 
features resembling autoimmune diseases (3).  88 
Allogenic HSCT patients are given a conditioning regimen to maximise cytoreductive therapy 89 
and decrease graft rejection, however, this can cause the cytokine storm (4). Cytokines, 90 
chemokines and their receptors play important roles in all phases of GVHD and their differential 91 
expression may be a determining factor of GVHD development and provide insight into its 92 
pathology (5, 6). To date several studies have investigated predictive and prognostic biomarkers 93 
for GVHD including cytokines and chemokines (7-15). However information regarding 94 
diagnostic, prognostic or predictive significance of these molecules in GVHD is limited. We 95 
selected candidate molecules from literature which had previously been associated with either 96 
aGVHD or cGVHD (16-19) for further validation as predictive, diagnostic or prognostic 97 
biomarkers. Donor derived T cells are involved in initiation of aGVHD but also play a role in 98 
cGVHD which has been classified as an independent disease (1). The ability of patients to 99 
develop cGVHD after T cell depletion suggests that other cell populations may play a role in its 100 
pathophysiology (20). B-cells play an important role in the immune response associated with 101 
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cGVHD and are involved in GVHD biology (3). cGVHD is associated with perturbed B cell 102 
homeostasis and B-cell activating factor (BAFF) is a key regulator of normal B-cell homeostasis 103 
in both mice and humans (21). Elevated levels of soluble BAFF have been reported in patients 104 
with autoimmune disease (22) and cGVHD (23). IL-33 is associated with inflammasome 105 
activation and danger signalling (24). Recently Toll-like receptors (TLRs) and Nucleotide 106 
Binding Oligomerization domain (NOD)-like receptors (NLRs) have been investigated in GVHD 107 
(25) (26). Both  TLRs and NLRs play a role in sensing danger signals (27) and with caspase-1 108 
are involved in the  formation of the multi-protein complex, inflammasome, which upon 109 
recognition of pathogens leads to the  release of IL-1β, IL-18 and IL-33 (28). Chemokines are 110 
small proteins that mediate migration of  leukocyte trafficking in vivo (29). The chemokines 111 
CXCL9, CXCL10 and CXCL11 are induced by interferon-γ (IFN) which is produced by Th1 112 
cells. The receptor for these ligands, CXCR3, is predominantly expressed on the surface of Th1 113 
cells and recent studies have demonstrated the involvement of the CXCR3 ligands in GVHD 114 
(18). 115 
In this study, the role of BAFF, IL-33, CXCL10 and CXCL11 was investigated in aGVHD and 116 
cGVHD, pre and post allo- HSCT patient sera in a training and validation set as biomarker 117 
candidates for prediction or prognosis of acute or cGVHD. Results were further validated in the 118 
clinical GVHD biopsies and the human in vitro skin explant model which can be used to induce 119 
a graft versus host reaction (GVHR,) using donor and recipient HLA matched skin and blood 120 
sample, as an in vitro model of GVHD (30-32).   121 
 122 
 123 
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Material and Methods 124 
Patients 125 
Patient samples were obtained after informed consent. This research was approved by Newcastle 126 
and North Tyneside Research Ethics Committee. Independent patient cohort samples were 127 
collected from two centres; Royal Victoria Infirmary, Newcastle (training cohort) and University 128 
Hospital, Regensburg (validation cohort). Patient clinical data was collected from the European 129 
Group of Blood and Marrow Transplantation (EBMT) database (https://www.ebmt.org.) Patient 130 
clinical characteristics and sample/cohort size are summarised in Table 1. Sample/cohort size 131 
was based on previous studies in this research group and has shown to be of adequate power. 132 
Patients at both centres received either myeloablative or reduced intensity conditioning (RIC) 133 
regimens. Healthy blood donors (from Newcastle) were used as normal controls to determine 134 
baseline levels/expression of biomarkers and compared to samples from GVHD patients taken 135 
post-HSCT. Diagnosis of aGVHD was according to clinical and histopathological criteria (33) 136 
and cGVHD by clinical assessment based on NIH criteria (34).  137 
 138 
Patient samples 139 
In both centres peripheral blood and serum was collected from HSCT recipient patients before 140 
conditioning (7 days pre- transplant) and at days 0, 7, 14, 28 and months 3, 6 and 12 following 141 
HSCT. Recipient skin biopsies for skin explant experiments were obtained pre-transplant and 142 
diagnostic skin/gut biopsies (4mm) were obtained at suspected clinical aGVHD onset post-143 
transplant.  144 
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 145 
ELISA 146 
Soluble BAFF (R&D Systems-US) and soluble IL-33 (APOTECH Corporation-Switzerland) 147 
levels were measured in patient sera in duplicate by enzyme-linked immunosorbent assay 148 
(ELISA) kits following the manufacturer’s recommended procedure.  149 
 150 
FACS Analysis 151 
CXCL10 and CXCL11 levels were measured with a Cytometric Bead Array flex set (BD 152 
Biosciences-US) in duplicate. Data was acquired on a FACS Calibur and analysed using FCAP 153 
software (BD Biosciences-US).  154 
 155 
Skin Explant Model 156 
The skin explant assay was performed as previously described (30, 31) (for brief explanation see 157 
supplementary data).   158 
 159 
Immunohistochemistry  160 
Immunohistochemistry was performed on 3µM sections from in vitro skin explants, skin or gut 161 
biopsies from GVHD patients. BAFF and IL-33 (ApoTECH-Switzerland), CXCL10 (Peprotech-162 
UK) and CXCL11 expression (Santa-Cruz) staining was performed using an automated 163 
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immunostainer (Ventana, Benchmark-US). Staining was performed in duplicate. Negative 164 
control sections were stained without the primary antibody. Expression analysis was performed 165 
by counting the percentage of positive cells in each section in proportion to the total number of 166 
cells.  167 
 168 
RNA extraction, cDNA production and Real Time PCR 169 
RNA was extracted from healthy volunteer skin samples, clinical GVHD skin biopsies or skin 170 
explant assay samples, using the mirVana miRNA Isolation Kit (Ambion-UK). cDNA was 171 
generated by random hexamer priming. Real time PCR was performed using TaqMan assays for 172 
CXCL10 (Hs00171042_m1), CXCL11 (Hs00171138_m1) and BAFF (Hs00198106_m1) and the 173 
control gene GAPDH (Life Technologies-UK). Reactions were set up in triplicate. A 7900 qRT-174 
PCR system (Life Technologie-UKs) was used to run reactions and analysis (SDS 2.3 software). 175 
The relative changes in RNA expression were calculated using the comparative ΔΔCt method 176 
(35). 177 
 178 
 Statistical analysis  179 
Non-parametric Mann-Whitney U test, 2 sample proportion test and chi square tests were used to 180 
compare changes in cytokine/chemokine levels in skin explant assays, biopsies and patient sera. 181 
A comparison was made at each time point between patients with or without aGVHD or 182 
cGVHD.  mRNA expression of biomarkers in positive (grade II>) and negative (less than grade 183 
II) skin explant assays were compared to medium alone controls. Skin explant GVHR grade was 184 
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compared with clinical aGVHD outcome. The diagnostic performance of each biomarker was 185 
evaluated using Receiver Operating Characteristic (ROC) curve analysis (method explained in 186 
supplementary data). Statistical analysis was carried out using Prism V5 (GraphPad). A 187 
probability (p) < 0.05 was considered to be statistically significant. P value index *= p<0.01, 188 
**=p<0.001 and ***=p<0.0001. Results are displayed in graphs as distribution of values 189 
measured with centre values as mean with s.e.m. 190 
 191 
 192 
 193 
 194 
 195 
 196 
 197 
 198 
 199 
 200 
 201 
 202 
 203 
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RESULTS 204 
Cytokine/chemokine levels in HSCT patient sera 205 
Serum BAFF (sBAFF) levels were measured in recipient HSCT patients in a training cohort 206 
(Newcastle), validation cohort (Regensburg) and healthy individuals. Interestingly, sBAFF levels 207 
were significantly elevated pre-transplant in the aGVHD group compared to the no-aGVHD 208 
group in the training and validation cohort (Table 2, Figure 1A). Following conditioning sBAFF 209 
levels decreased on day 0 in the aGVHD group compared to pre-transplant levels in the same 210 
group in both cohorts (training, p=0.01) (validation, p=0.04) (Figure 1A). Post-transplant, 211 
sBAFF levels were significantly elevated on day 14 in the aGVHD group compared to the no-212 
aGVHD group in the both cohorts (Table 2, Figure 1A). sBAFF levels in healthy individuals 213 
were significantly lower (p=0.0003) compared to HSCT patients pre-transplant (Figure 1A). 214 
Development of aGVHD usually precedes cGVHD (36), within the training cohort (n=54) 45% 215 
of no-aGVHD patients developed cGVHD, compared with 75% of patients with aGVHD 216 
(p=0.04). This confirms the risk of developing cGVHD is higher in the aGVHD group (37) and 217 
therefore may confirm BAFF as a predictive biomarker in cGVHD as recently reported (17, 23). 218 
In cGVHD patients, sBAFF levels were significantly elevated at 12 months post-transplant in the 219 
training cohort and 6 and 12 months post-transplant in the validation cohort compared to the no-220 
cGVHD group (Table 2, Figure 1B). The onset of cGVHD at 6 months post-transplant correlated 221 
with increased sBAFF levels (p=0.02, data not shown) in the training cohort. Increased sBAFF 222 
levels at 12 months in both cohorts suggests BAFF is indeed implicated in cGVHD and could 223 
serve as a diagnostic biomarker for cGVHD. 224 
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Treatment of patients with cGVHD often comprises steroid administration which can reduce 225 
BAFF levels (38, 39). Patients in the training cohort treated with steroids had lower sBAFF 226 
levels compared to patients without steroid treatment (data not shown). However, in the 227 
validation cohort, patients treated with steroids showed increased sBAFF levels at 6 months 228 
(p=0.002, data not shown). In both cohorts the majority of patients were administered with low 229 
dose steroids (1-2mg/kg), 2 patients from the training cohort and 1 patient from the validation 230 
cohort received high dose steroids (>2mg/kg). Data analysis in relation to the different 231 
conditioning regimens showed no difference in sBAFF levels between patients receiving RIC or 232 
myeloablative conditioning treatments (data not shown).  233 
Next we investigated levels of cytokine IL-33 in both cohorts. Soluble IL-33 levels were 234 
significantly higher in the aGVHD group compared to the no-aGVHD group on day 0 and day 28 235 
post-transplant in the training cohort and day 28 in the validation cohort (Table 2, Figure 1C) 236 
indicating a potential role of IL-33 in predicting GVHD. sIL-33 levels in patients with cGVHD 237 
showed a significant increase at 3 months post-transplant (*p=0.03) in the cGVHD group which 238 
could possibly be a continuation of aGVHD. However, in the validation cohort a significant 239 
decrease was observed in cGVHD patients compared to the no-cGVHD group (Table 2, Figure 240 
1D).  241 
We then analysed CXCL10 and CXCL11 levels. CXCL10 levels were significantly increased 242 
pre-transplant in the aGVHD group in the training cohort only. Post-transplant, CXCL10 was 243 
significantly decreased in the training cohort aGVHD group on day 0 but then significantly 244 
increased on day 14 and 28 post-transplant compared to patients with no-aGVHD. 245 
Correspondingly, a significant increase was also observed in the validation cohort on day 14 and 246 
28 (Table 2, Figure 2A) confirming an important role for CXCL10 in aGVHD. CXCL11 levels 247 
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were also increased pre-transplant in aGVHD patients (*p=0.03) in the training cohort only.  248 
Post-transplant a significant increase was observed in both cohorts on day 14 and 28 in aGVHD 249 
patients (Table 2, Figure 2C). In cGVHD patients, CXCL10 levels in the training cohort were 250 
significantly increased at 3, 6 and 12 months post-transplant. This was confirmed at 6 and 12 251 
months post-transplant in the validation cohort (Table 2, Figure 2B). CXCL11 levels in cGVHD 252 
patients were significantly increased at 6 and 12 months post-transplant in the training cohort and 253 
significantly increased at 3, 6 and 12 months in the validation cohort (Table 2, Figure 2D).  The 254 
corresponding results from both cohorts confirm the suitability of CXCL10 and CXCL11 as 255 
diagnostic biomarkers for acute and cGVHD. The expression of pro-inflammatory chemokines in 256 
target tissues has been shown to be dependent on the conditioning regimen (40) and reported to 257 
be significantly increased after conditioning in comparison to normal controls. We also 258 
demonstrated increased levels of both CXCL10 and CXCL11 levels after either myeloablative or 259 
reduced intensity conditioning (see supplementary data).  260 
 261 
Receiver Operating Characteristic curves 262 
Training and validation cohort results were combined to determine diagnostic performance of 263 
each biomarker by ROC curve analysis pre/post-transplant for aGVHD and cGVHD. The 3 264 
months post-transplant time-point was excluded as no significant changes were observed.  An 265 
AUC between 0.9-1.0 is considered excellent, between 0.8-0.9 good, 0.7-0.8 fair and 0.6-0.7 266 
poor. Biomarkers which gave an AUC of 75 > are listed in Figure 3. For aGVHD the AUC for 267 
IL-33 at day 0 was 0.78 and for CXCL10 at day 14 was 0.79. For cGVHD the AUC was good 268 
for all biomarkers at 12 months post-transplant (BAFF 0.85, IL-33 0.80, CXCL10 0.79 and 269 
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CXCL11 0.75) at 6 months post-transplant for BAFF (0.75) and pre-transplant for CXCL10 270 
(0.78).   271 
 272 
Confirmatory studies on skin explants and clinical biopsies 273 
1. Cytokine/chemokine expression in the human in-vitro skin explant assay 274 
We investigated BAFF, IL-33, CXCL10 and CXCL11 protein expression in skin explant assays. 275 
BAFF expression was analysed in 23 allogeneic skin explants. The GVHR results were 276 
correlated with clinical aGVHD outcome for each patient and an 83% correlation (data not 277 
shown) was observed as previously reported (32). Controls were skin incubated in medium alone 278 
or with autologous cells. BAFF expression in controls was similar to GVHR grade 0-I explant 279 
assays (54%, 56%, respectively), but significantly increased in grade II-III GVHR explants 280 
(mean positive cells 66%, *p=0.04) (Figure 4A) demonstrating BAFF expression correlates with 281 
severity of GVHR. BAFF expression in normal healthy skin was significantly lower (p=0.01) 282 
compared to grades II-III GVHR (data not shown).  283 
IL-33 expression was analysed in 26 skin explant assays and was significantly increased 284 
(*p=0.004, Figure 4B) in grade II-III GVHR skin explants (mean positive cells 41%,) compared 285 
to grade 0-I GVHR (15%, data not shown). Normal healthy skin showed low IL-33 expression in 286 
comparison to skin explant assays (data not shown).  287 
CXCL10 and CXCL11 expression was analysed in 20 skin explant assays. CXCL10 expression 288 
was significantly increased in the II-III GVHR group in comparison to the control group 289 
(medium only) (*p=0.007). No difference was observed between the control group and the grade 290 
0-I GVHR group (Figure 4C). CXCL11 expression was significantly increased in grade II-III 291 
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GVHR skin explants compared to grade 0-I GVHR group (*p=0.01) (Figure 4D). Moreover, 292 
only basal levels of CXCL10 and CXCL11 were observed in normal healthy skin (data not 293 
shown).  294 
 295 
Cytokine/chemokine expression in clinical biopsies 296 
Clinical biopsies from HSCT patients were analysed for BAFF, IL-33 CXCL10 and CXCL11 297 
protein expression by immunohistochemistry using clinical gastrointestinal (GI) tract biopsies 298 
(n=17, 8 patients with clinical aGVHD and 9 patients with no-aGVHD). High BAFF expression 299 
was observed in 6/8 aGVHD biopsies (Figure 5A), no-aGVHD biopsies tested negative for 300 
BAFF staining (p=0.001). The aGVHD GI biopsies all showed positive IL-33 staining (66.7% 301 
positive cells p=0.01) (Figure 5B) whereas 7/9 biopsies from no-aGVHD patients were negative. 302 
To investigate further, mRNA expression was investigated in clinical skin biopsies taken from 303 
allo-HSCT patient’s pre/post-transplant. BAFF mRNA expression in pre-transplant biopsies were 304 
used as calibrator for expression in post-transplant biopsies and the histopathological aGVHD 305 
grades were used for analysis. BAFF mRNA expression was 23 fold-higher in aGVHD (grade II-306 
III) patients (n=8) in comparison to no-aGVHD (grade 0-1) patients (n=15) (p=0.019) (Figure 307 
6E) and significantly lower in normal healthy control skin biopsies compared to no-aGVHD 308 
patients (p=0.03) and aGVHD (p=0.007) (data not shown). CXCL10 and CXCL11 mRNA 309 
expression, showed 10/17 (CXCL10) and 12/17 (CXCL11) aGVHD post-HSCT clinical biopsies 310 
tested positive. However CXCL10 (Figure 5C) and CXCL11 (Figure 5D) expression was more 311 
strongly distinctive in biopsies from patients with aGVHD. CXCL10 and CXCL11 mRNA 312 
expression in normal and clinical aGVHD skin showed low levels in normal skin, and 313 
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significantly increased in aGVHD skin (p=0.001 and p=0.0003, respectively) (Figure 6A and 314 
6B).  Moreover, gene expression of CXCL10 and CXCL11 was also significantly increased in 315 
GVHR (grade II-III) positive skin explants (Figure 6C and 6D) in comparison to the medium 316 
control (p=0.02, p=0.02). 317 
 318 
 319 
 320 
 321 
 322 
 323 
 324 
 325 
 326 
 327 
 328 
 329 
 330 
 331 
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DISCUSSION 332 
Elevated BAFF levels were previously reported in plasma of cGVHD patients (17, 23). Our 333 
results show sBAFF levels were already elevated pre-transplant in patients subsequently 334 
developing aGVHD indicating graft outcome may be influenced by transplant factors such as 335 
BAFF.  Decreased sBAFF levels at day 0 suggested an effect of the conditioning treatment on 336 
BAFF producing cells. Following conditioning a defect in cell mediated immunity occurs 337 
resulting in disruption of B cell homeostasis causing slow B cell reconstitution and impaired 338 
functionality (41). The sustained increase in BAFF levels observed in aGVHD patients following 339 
HSCT suggested delayed B cell recovery which may have contributed to loss of B cell tolerance 340 
and development of cGVHD (42). Elevated BAFF mRNA and protein expression confirmed its 341 
association with increased risk of developing aGVHD. Moreover, increased sBAFF levels in 342 
cGVHD patients provided strong support for BAFF involvement in cGVHD with pre-transplant 343 
levels predicting aGVHD outcome. Therefore, BAFF can be important for diagnosis or 344 
monitoring GVHD in response to acute and cGVHD therapy. Similarly sIL-33 data suggests an 345 
important role for IL-33 in development of aGVHD as recently reported (43).  346 
Chemokines have been implicated in allogeneic transplant rejection (44, 45). The CXCR3 347 
receptor and its ligands CXCL9/10/11 constitute an important pathway for effector cell 348 
recruitment post-transplant (19, 46). Increased CXCL10 levels in sera and aGVHD skin biopsies 349 
(18, 47) have been reported but no involvement in cGVHD. The increase in CXCL10/CXCL11 350 
levels in acute and cGVHD patient sera suggests a potential biomarker role for both chemokines 351 
and suggests he perseverance of elevated CXCL10/CXCL11 levels during aGVHD may lead to 352 
cGVHD development. Both CXCL10/CXCL11 where strongly influenced by conditioning 353 
treatment indicating conditioning induces early chemokine expression promoting T cell 354 
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migration into GVHD target organs and GVHD. Activation of chemokine expression using skin 355 
explant assays has recently been shown to induce T cell migration and IFNγ secretion 356 
exacerbating the GVHR (48). 357 
Interestingly, the biomarkers investigated work collectively downstream of each another in 358 
inflammatory response initiation. Inflammasome assembly at tissue damage sites results in 359 
caspase-1 release (49) and subsequent IL-33 activation (50) and binding to its receptor ST2 360 
(suppressor of tumorgenicity-2). This elicits danger signals recognized by immune cells which 361 
initiate an inflammatory response and express the CXCR3 receptor on the cell surface, resulting 362 
in CXCL10/CXCL11 binding and infiltration of effector T cells. ST2 itself has recently 363 
implicated as a biomarker for aGVHD (51) .    364 
In conclusion the training and validation cohort results highlight association of the investigated 365 
biomarkers to GVHD. Independent evaluation of the biomarkers in clinical biopsies and the skin 366 
explants strongly confirms association of each biomarker in predictive or diagnostic roles in 367 
acute or chronic GVHD. Our results show a combination of different markers can be used to 368 
predict both acute and cGVHD, however, use of a biomarker panel may be more effective to 369 
predict GVHD occurrence (52).  370 
 371 
 372 
 373 
 374 
Supplementary information is available at BMT's website 375 
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 545 
 546 
Figure Legends 547 
Figure 1.  sBAFF and sIL-33 levels in HSCT patient sera measured pre-transplant and at 548 
selected time-points post-transplant. Results are given for the training cohort (black bars) and 549 
validation cohort (grey bars) in HSCT patients with and without acute GVHD (left) and cGVHD 550 
(right). Graph shows mean sBAFF and sIL-33 levels (ng/ml) at each time-point tested. Results 551 
are shown for A; healthy individuals (Normal, in training cohort only n=8) and sBAFF levels in 552 
HSCT patients with and without acute GVHD.  B; sBAFF levels in HSCT patients with and 553 
without chronic GVHD. C; sIL-33 levels in HSCT patients with and without acute GVHD. D; 554 
sIL-33 levels in HSCT patients with and without chronic GVHD. P values indicated as *= 555 
p<0.01, **=p<0.001 and ***=p<0.0001  556 
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 557 
Figure 2. sCXCL10 and sCXCL11 levels in HSCT patient sera measured pre-transplant 558 
and at different time-points post-transplant. . Results are given for the training cohort (black 559 
bars) and validation cohort (grey bars) in HSCT patients with and without acute GVHD (left) 560 
and cGVHD (right). Graph shows mean sCXCL10 and CXCL11 levels (pg/ml) at each time-561 
point tested. A; healthy individuals (Norm, in training cohort only) and sCXCL10 levels in 562 
HSCT patients with and without acute GVHD, B; sCXCL10 levels in HSCT patients with and 563 
without chronic GVHD. C; sCXCL10 levels in HSCT patients with and without chronic GVHD. 564 
D; sCXCL11 levels in HSCT patients with and without chronic GVHD. P values indicated as *= 565 
p<0.01, **=p<0.001 and ***=p<0.0001.  566 
 567 
Figure 3. Receiver Operating Characteristic (ROC) curve data for predicting aGVHD and 568 
cGVHD. A, The area under the curve (AUC), standard error (S.E.), P value and optimal cut-off 569 
point is given for biomarkers which showed an AUC of 0.75 or above for acute or chronic 570 
GVHD patients. B, a representative image of ROC analysis of HSCT patients with chronic 571 
GVHD 12 months post-transplant.  572 
 573 
Figure 4. Cytokine/chemokine expression in in-vitro skin explants of HSCT patients. Box 574 
plots show the overall percentage of cells which stained positive for each cytokine/chemokine. 575 
A, BAFF expression was significantly (p=0.04) increased in GVHR positive skin explant assays 576 
(n=17 grade II-III GVHR) compared to GVHR negative skin explants (n=6, grade 0-I GVHR). 577 
B, IL-33 expression was significantly (p=0.004) increased in GVHR positive skin explant assays 578 
(n=19 grade II-III GVHR) compared to GVHR negative skin explants (n=7, grade 0-I GVHR) C, 579 
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CXCL10 and D, CXCL11 expression was significantly increased (p=0.007 and p=0.01, 580 
respectively) in GVHR positive skin explant assays compared to GVHR negative skin explants. 581 
Representative immunohistochemistry images are given below each box plot showing expression 582 
in a GVHR negative skin explant and a GVHR positive skin explant for each 583 
cytokine/chemokine.  All images were acquired using a light microscope (Leitz Wetzer) at x 50 584 
magnification (1.32 OPL) and a digital camera (Canon, DS126071; Canon Utilities Browser EX 585 
software).  586 
 587 
Figure 5. Cytokine/chemokine expression in clinical biopsies of HSCT patients. 588 
Representative immunohistochemistry images of gastrointestinal tract biopsies of aGVHD 589 
patients (left) and HSCT patients with no acute GVHD (right). A, Membrane-bound staining of 590 
BAFF in a gut biopsy of an acute GVHD patient (left) and duodenum biopsy of HSCT patient 591 
with no acute GVHD (right). B, IL-33, C, CXCL10 and D, CXCL11 staining in a gut biopsy of 592 
an acute GVHD patient (left) and of HSCT patient with no aGVHD right. All images were 593 
acquired using a light microscope (Leitz Wetzer) at x 50 magnification (1.32 OPL) and a digital 594 
camera (Canon, DS126071; Canon Utilities Browser EX software).  595 
 596 
Figure 6. CXCL10, CXCL11 and BAFF mRNA expression analysis in aGVHD clinical skin 597 
biopsies and in skin explant assays by RTPCR. 598 
Graphs show mRNA expression in either clinical skin biopsies from HSCT aGVHD patients in 599 
comparison to expression in normal healthy individuals or mRNA expression in skin explants 600 
compared to medium control (skin incubated in medium alone). The point 0 (dotted line) defines 601 
the expression of mRNA above or below this point.  A, CXCL10 and B, CXCL11 expression in 602 
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acute GVHD clinical biopsies was significantly increased in comparison to normal skin (control) 603 
(p=0.001, p=0.0003). C, CXCL10 and D, CXCL11  expression in GVHR grade III skin explants 604 
was significantly increased when compared to medium control (p=0.02, p=0.02) (Mann Whitney 605 
U test). E, Quantitative RT-qPCR analysis of BAFF mRNA expression in acute GVHD clinical 606 
skin biopsies. Results are given relative to GAPDH and BAFF expression in pre-HSCT biopsies. 607 
BAFF expression was significantly higher in grades II-III acute GVHD patient biopsies in 608 
comparison to grades 0-I aGVHD. Mann-Whitney U test was used to determine significance.  609 
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Abstract 57 
Graft versus host disease (GVHD) is a major complication of haematopoietic stem cell 58 
transplantation (HSCT). A number of inflammatory cytokines/chemokines are implicated in 59 
GVHD and have been identified in numerous single centre studies as potential biomarkers for 60 
acute and/or chronic GVHD. In this study we analysed candidate inflammatory biomarkers 61 
(BAFF, interleukin 33 (IL-33), CXCL10 and CXCL11) in a two centre study. Biomarkers were 62 
evaluated pre-transplant and at serial time-points post-transplant in acute and chronic GVHD 63 
patient sera with time-matched control samples from patients without GVHD. Further validation 64 
was performed using the human skin explant assay, clinical GVHD biopsies and mRNA 65 
expression analysis. 66 
 BAFF was significantly increased pre-transplant. BAFF, IL-33, CXCL10 and CXCL11 showed 67 
increased levels in acute GVHD patient sera and high protein expression in grades II-III of the in 68 
vitro skin explant graft versus host reaction (GVHR) group. BAFF, CXCL10 and CXCL11 also 69 
showed increased mRNA expression levels in clinical biopsies compared to the no/low grade 70 
GVHD group. BAFF, CXCL10 and CXCL11 levels were increased in chronic GVHD patient 71 
sera.  The results identify BAFF and CXCL10 as predictive biomarkers for acute GVHD and 72 
BAFF, CXCL10 and CXCL11 as useful diagnostic biomarkers for acute GVHD and chronic 73 
GVHD.  74 
 75 
 76 
 77 
 78 
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Introduction 79 
Haematopoietic stem cell transplantation (HSCT) is increasingly used to treat patients suffering 80 
malignant and non-malignant haematopoietic disorders. A frequent and potentially life 81 
threatening complication is graft-versus-host disease (GVHD) whereby donor T-cells attack host 82 
target organs causing substantial damage and apoptosis of cells giving rise to clinical symptoms 83 
of acute GVHD (aGVHD) followed by chronic GVHD (cGVHD). Severity of aGVHD is graded 84 
according to the number of organs involved and the severity of organ dysfunction (1) and occurs 85 
shortly after transplant whereas cGVHD either overlaps with aGVHD or is more delayed (after 86 
100 days). The aGVHD process largely involves apoptosis and necrosis (2) with cGVHD having 87 
features resembling autoimmune diseases (3).  88 
Allogenic HSCT patients are given a conditioning regimen to maximise cytoreductive therapy 89 
and decrease graft rejection, however, this can cause the cytokine storm (4). Cytokines, 90 
chemokines and their receptors play important roles in all phases of GVHD and their differential 91 
expression may be a determining factor of GVHD development and provide insight into its 92 
pathology (5, 6). To date several studies have investigated predictive and prognostic biomarkers 93 
for GVHD including cytokines and chemokines (7-15). However information regarding 94 
diagnostic, prognostic or predictive significance of these molecules in GVHD is limited. We 95 
selected candidate molecules from literature which had previously been associated with either 96 
aGVHD or cGVHD (16-19) for further validation as predictive, diagnostic or prognostic 97 
biomarkers. Donor derived T cells are involved in initiation of aGVHD but also play a role in 98 
cGVHD which has been classified as an independent disease (1). The ability of patients to 99 
develop cGVHD after T cell depletion suggests that other cell populations may play a role in its 100 
pathophysiology (20). B-cells play an important role in the immune response associated with 101 
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cGVHD and are involved in GVHD biology (3). cGVHD is associated with perturbed B cell 102 
homeostasis and B-cell activating factor (BAFF) is a key regulator of normal B-cell homeostasis 103 
in both mice and humans (21). Elevated levels of soluble BAFF have been reported in patients 104 
with autoimmune disease (22) and cGVHD (23). IL-33 is associated with inflammasome 105 
activation and danger signalling (24). Recently Toll-like receptors (TLRs) and Nucleotide 106 
Binding Oligomerization domain (NOD)-like receptors (NLRs) have been investigated in GVHD 107 
(25) (26). Both  TLRs and NLRs play a role in sensing danger signals (27) and with caspase-1 108 
are involved in the  formation of the multi-protein complex, inflammasome, which upon 109 
recognition of pathogens leads to the  release of IL-1β, IL-18 and IL-33 (28). Chemokines are 110 
small proteins that mediate migration of  leukocyte trafficking in vivo (29). The chemokines 111 
CXCL9, CXCL10 and CXCL11 are induced by interferon-γ (IFN) which is produced by Th1 112 
cells. The receptor for these ligands, CXCR3, is predominantly expressed on the surface of Th1 113 
cells and recent studies have demonstrated the involvement of the CXCR3 ligands in GVHD 114 
(18). 115 
In this study, the role of BAFF, IL-33, CXCL10 and CXCL11 was investigated in aGVHD and 116 
cGVHD, pre and post allo- HSCT patient sera in a training and validation set as biomarker 117 
candidates for prediction or prognosis of acute or cGVHD. Results were further validated in the 118 
clinical GVHD biopsies and the human in vitro skin explant model which can be used to induce 119 
a graft versus host reaction (GVHR,) using donor and recipient HLA matched skin and blood 120 
sample, as an in vitro model of GVHD (30, 31).   121 
 122 
 123 
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Material and Methods 124 
Patients 125 
Patient samples were obtained after informed consent. This research was approved by Newcastle 126 
and North Tyneside Research Ethics Committee. Independent patient cohort samples were 127 
collected from two centres; Royal Victoria Infirmary, Newcastle (training cohort) and University 128 
Hospital, Regensburg (validation cohort). Patient clinical data was collected from the European 129 
Group of Blood and Marrow Transplantation (EBMT) database (https://www.ebmt.org.) Patient 130 
clinical characteristics and sample/cohort size are summarised in Table 1. Sample/cohort size 131 
was based on previous studies in this research group and has shown to be of adequate power. 132 
Patients at both centres received either myeloablative or reduced intensity conditioning (RIC) 133 
regimens. Healthy blood donors (from Newcastle) were used as normal controls to determine 134 
baseline levels/expression of biomarkers and compared to samples from GVHD patients taken 135 
post-HSCT. Diagnosis of aGVHD was according to clinical and histopathological criteria (32) 136 
and cGVHD by clinical assessment based on NIH criteria (33).  137 
 138 
Patient samples 139 
In both centres peripheral blood and serum was collected from HSCT recipient patients before 140 
conditioning (7 days pre- transplant) and at days 0, 7, 14, 28 and months 3, 6 and 12 following 141 
HSCT. Recipient skin biopsies for skin explant experiments were obtained pre-transplant and 142 
diagnostic skin/gut biopsies (4mm) were obtained at suspected clinical aGVHD onset post-143 
transplant.  144 
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 145 
ELISA 146 
Soluble BAFF (R&D Systems-US) and soluble IL-33 (APOTECH Corporation-Switzerland) 147 
levels were measured in patient sera in duplicate by enzyme-linked immunosorbent assay 148 
(ELISA) kits following the manufacturer’s recommended procedure.  149 
 150 
FACS Analysis 151 
CXCL10 and CXCL11 levels were measured with a Cytometric Bead Array flex set (BD 152 
Biosciences-US) in duplicate. Data was acquired on a FACS Calibur and analysed using FCAP 153 
software (BD Biosciences-US).  154 
 155 
Skin Explant Model 156 
The skin explant assay was performed as previously described (30, 31) (for brief explanation see 157 
supplementary data).   158 
 159 
Immunohistochemistry  160 
Immunohistochemistry was performed on 3µM sections from in vitro skin explants, skin or gut 161 
biopsies from GVHD patients. BAFF and IL-33 (ApoTECH-Switzerland), CXCL10 (Peprotech-162 
UK) and CXCL11 expression (Santa-Cruz) staining was performed using an automated 163 
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immunostainer (Ventana, Benchmark-US). Staining was performed in duplicate. Negative 164 
control sections were stained without the primary antibody. Expression analysis was performed 165 
by counting the percentage of positive cells in each section in proportion to the total number of 166 
cells.  167 
 168 
RNA extraction, cDNA production and Real Time PCR 169 
RNA was extracted from healthy volunteer skin samples, clinical GVHD skin biopsies or skin 170 
explant assay samples, using the mirVana miRNA Isolation Kit (Ambion-UK). cDNA was 171 
generated by random hexamer priming. Real time PCR was performed using TaqMan assays for 172 
CXCL10 (Hs00171042_m1), CXCL11 (Hs00171138_m1) and BAFF (Hs00198106_m1) and the 173 
control gene GAPDH (Life Technologies-UK). Reactions were set up in triplicate. A 7900 qRT-174 
PCR system (Life Technologie-UKs) was used to run reactions and analysis (SDS 2.3 software). 175 
The relative changes in RNA expression were calculated using the comparative ΔΔCt method 176 
(34). 177 
 178 
 Statistical analysis  179 
Non-parametric Mann-Whitney U test, 2 sample proportion test and chi square tests were used to 180 
compare changes in cytokine/chemokine levels in skin explant assays, biopsies and patient sera. 181 
A comparison was made at each time point between patients with or without aGVHD or 182 
cGVHD.  mRNA expression of biomarkers in positive (grade II>) and negative (less than grade 183 
II) skin explant assays were compared to medium alone controls. Skin explant GVHR grade was 184 
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compared with clinical aGVHD outcome. The diagnostic performance of each biomarker was 185 
evaluated using Receiver Operating Characteristic (ROC) curve analysis (method explained in 186 
supplementary data). Statistical analysis was carried out using Prism V5 (GraphPad). A 187 
probability (p) < 0.05 was considered to be statistically significant. P value index *= p<0.01, 188 
**=p<0.001 and ***=p<0.0001. Results are displayed in graphs as distribution of values 189 
measured with centre values as mean with s.e.m. 190 
 191 
 192 
 193 
 194 
 195 
 196 
 197 
 198 
 199 
 200 
 201 
 202 
 203 
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RESULTS 204 
Cytokine/chemokine levels in HSCT patient sera 205 
Serum BAFF (sBAFF) levels were measured in recipient HSCT patients in a training cohort 206 
(Newcastle), validation cohort (Regensburg) and healthy individuals. Interestingly, sBAFF levels 207 
were significantly elevated pre-transplant in the aGVHD group compared to the no-aGVHD 208 
group in the training and validation cohort (Table 2, Figure 1A). Following conditioning sBAFF 209 
levels decreased on day 0 in the aGVHD group compared to pre-transplant levels in the same 210 
group in both cohorts (training, p=0.01) (validation, p=0.04) (Figure 1A). Post-transplant, 211 
sBAFF levels were significantly elevated on day 14 in the aGVHD group compared to the no-212 
aGVHD group in the both cohorts (Table 2, Figure 1A). sBAFF levels in healthy individuals 213 
were significantly lower (p=0.0003) compared to HSCT patients pre-transplant (Figure 1A). 214 
Development of aGVHD usually precedes cGVHD (35), within the training cohort (n=54) 45% 215 
of no-aGVHD patients developed cGVHD, compared with 75% of patients with aGVHD 216 
(p=0.04). This confirms the risk of developing cGVHD is higher in the aGVHD group (36) and 217 
therefore may confirm BAFF as a predictive biomarker in cGVHD as recently reported (17, 23). 218 
In cGVHD patients, sBAFF levels were significantly elevated at 12 months post-transplant in the 219 
training cohort and 6 and 12 months post-transplant in the validation cohort compared to the no-220 
cGVHD group (Table 2, Figure 1B). The onset of cGVHD at 6 months post-transplant correlated 221 
with increased sBAFF levels (p=0.02, data not shown) in the training cohort. Increased sBAFF 222 
levels at 12 months in both cohorts suggests BAFF is indeed implicated in cGVHD and could 223 
serve as a diagnostic biomarker for cGVHD. 224 
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Treatment of patients with cGVHD often comprises steroid administration which can reduce 225 
BAFF levels (37, 38). Patients in the training cohort treated with steroids had lower sBAFF 226 
levels compared to patients without steroid treatment (data not shown). However, in the 227 
validation cohort, patients treated with steroids showed increased sBAFF levels at 6 months 228 
(p=0.002, data not shown). In both cohorts the majority of patients were administered with low 229 
dose steroids (1-2mg/kg), 2 patients from the training cohort and 1 patient from the validation 230 
cohort received high dose steroids (>2mg/kg). Data analysis in relation to the different 231 
conditioning regimens showed no difference in sBAFF levels between patients receiving RIC or 232 
myeloablative conditioning treatments (data not shown).  233 
Next we investigated levels of cytokine IL-33 in both cohorts. Soluble IL-33 levels were 234 
significantly higher in the aGVHD group compared to the no-aGVHD group on day 0 and day 28 235 
post-transplant in the training cohort and day 28 in the validation cohort (Table 2, Figure 1C) 236 
indicating a potential role of IL-33 in predicting GVHD. sIL-33 levels in patients with cGVHD 237 
showed a significant increase at 3 months post-transplant (*p=0.03) in the cGVHD group which 238 
could possibly be a continuation of aGVHD. However, in the validation cohort a significant 239 
decrease was observed in cGVHD patients compared to the no-cGVHD group (Table 2, Figure 240 
1D).  241 
We then analysed CXCL10 and CXCL11 levels. CXCL10 levels were significantly increased 242 
pre-transplant in the aGVHD group in the training cohort only. Post-transplant, CXCL10 was 243 
significantly decreased in the training cohort aGVHD group on day 0 but then significantly 244 
increased on day 14 and 28 post-transplant compared to patients with no-aGVHD. 245 
Correspondingly, a significant increase was also observed in the validation cohort on day 14 and 246 
28 (Table 2, Figure 2A) confirming an important role for CXCL10 in aGVHD. CXCL11 levels 247 
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were also increased pre-transplant in aGVHD patients (*p=0.03) in the training cohort only.  248 
Post-transplant a significant increase was observed in both cohorts on day 14 and 28 in aGVHD 249 
patients (Table 2, Figure 2C). In cGVHD patients, CXCL10 levels in the training cohort were 250 
significantly increased at 3, 6 and 12 months post-transplant. This was confirmed at 6 and 12 251 
months post-transplant in the validation cohort (Table 2, Figure 2B). CXCL11 levels in cGVHD 252 
patients were significantly increased at 6 and 12 months post-transplant in the training cohort and 253 
significantly increased at 3, 6 and 12 months in the validation cohort (Table 2, Figure 2D).  The 254 
corresponding results from both cohorts confirm the suitability of CXCL10 and CXCL11 as 255 
diagnostic biomarkers for acute and cGVHD. The expression of pro-inflammatory chemokines in 256 
target tissues has been shown to be dependent on the conditioning regimen (39) and reported to 257 
be significantly increased after conditioning in comparison to normal controls. We also 258 
demonstrated increased levels of both CXCL10 and CXCL11 levels after either myeloablative or 259 
reduced intensity conditioning (see supplementary data).  260 
 261 
Receiver Operating Characteristic curves 262 
Training and validation cohort results were combined to determine diagnostic performance of 263 
each biomarker by ROC curve analysis pre/post-transplant for aGVHD and cGVHD. The 3 264 
months post-transplant time-point was excluded as no significant changes were observed.  An 265 
AUC between 0.9-1.0 is considered excellent, between 0.8-0.9 good, 0.7-0.8 fair and 0.6-0.7 266 
poor. Biomarkers which gave an AUC of 75 > are listed in Figure 3. For aGVHD the AUC for 267 
IL-33 at day 0 was 0.78 and for CXCL10 at day 14 was 0.79. For cGVHD the AUC was good 268 
for all biomarkers at 12 months post-transplant (BAFF 0.85, IL-33 0.80, CXCL10 0.79 and 269 
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CXCL11 0.75) at 6 months post-transplant for BAFF (0.75) and pre-transplant for CXCL10 270 
(0.78).   271 
 272 
Confirmatory studies on skin explants and clinical biopsies 273 
1. Cytokine/chemokine expression in the human in-vitro skin explant assay 274 
We investigated BAFF, IL-33, CXCL10 and CXCL11 protein expression in skin explant assays. 275 
BAFF expression was analysed in 23 allogeneic skin explants. The GVHR results were 276 
correlated with clinical aGVHD outcome for each patient and an 83% correlation (data not 277 
shown) was observed as previously reported (40). Controls were skin incubated in medium alone 278 
or with autologous cells. BAFF expression in controls was similar to GVHR grade 0-I explant 279 
assays (54%, 56%, respectively), but significantly increased in grade II-III GVHR explants 280 
(mean positive cells 66%, *p=0.04) (Figure 4A) demonstrating BAFF expression correlates with 281 
severity of GVHR. BAFF expression in normal healthy skin was significantly lower (p=0.01) 282 
compared to grades II-III GVHR (data not shown).  283 
IL-33 expression was analysed in 26 skin explant assays and was significantly increased 284 
(*p=0.004, Figure 4B) in grade II-III GVHR skin explants (mean positive cells 41%,) compared 285 
to grade 0-I GVHR (15%, data not shown). Normal healthy skin showed low IL-33 expression in 286 
comparison to skin explant assays (data not shown).  287 
CXCL10 and CXCL11 expression was analysed in 20 skin explant assays. CXCL10 expression 288 
was significantly increased in the II-III GVHR group in comparison to the control group 289 
(medium only) (*p=0.007). No difference was observed between the control group and the grade 290 
0-I GVHR group (Figure 4C). CXCL11 expression was significantly increased in grade II-III 291 
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GVHR skin explants compared to grade 0-I GVHR group (*p=0.01) (Figure 4D). Moreover, 292 
only basal levels of CXCL10 and CXCL11 were observed in normal healthy skin (data not 293 
shown).  294 
 295 
Cytokine/chemokine expression in clinical biopsies 296 
Clinical biopsies from HSCT patients were analysed for BAFF, IL-33 CXCL10 and CXCL11 297 
protein expression by immunohistochemistry using clinical gastrointestinal (GI) tract biopsies 298 
(n=17, 8 patients with clinical aGVHD and 9 patients with no-aGVHD). High BAFF expression 299 
was observed in 6/8 aGVHD biopsies (Figure 5A), no-aGVHD biopsies tested negative for 300 
BAFF staining (p=0.001). The aGVHD GI biopsies all showed positive IL-33 staining (66.7% 301 
positive cells p=0.01) (Figure 5B) whereas 7/9 biopsies from no-aGVHD patients were negative. 302 
To investigate further, mRNA expression was investigated in clinical skin biopsies taken from 303 
allo-HSCT patient’s pre/post-transplant. BAFF mRNA expression in pre-transplant biopsies were 304 
used as calibrator for expression in post-transplant biopsies and the histopathological aGVHD 305 
grades were used for analysis. BAFF mRNA expression was 23 fold-higher in aGVHD (grade II-306 
III) patients (n=8) in comparison to no-aGVHD (grade 0-1) patients (n=15) (p=0.019) (Figure 307 
6E) and significantly lower in normal healthy control skin biopsies compared to no-aGVHD 308 
patients (p=0.03) and aGVHD (p=0.007) (data not shown). CXCL10 and CXCL11 mRNA 309 
expression, showed 10/17 (CXCL10) and 12/17 (CXCL11) aGVHD post-HSCT clinical biopsies 310 
tested positive. However CXCL10 (Figure 5C) and CXCL11 (Figure 5D) expression was more 311 
strongly distinctive in biopsies from patients with aGVHD. CXCL10 and CXCL11 mRNA 312 
expression in normal and clinical aGVHD skin showed low levels in normal skin, and 313 
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significantly increased in aGVHD skin (p=0.001 and p=0.0003, respectively) (Figure 6A and 314 
6B).  Moreover, gene expression of CXCL10 and CXCL11 was also significantly increased in 315 
GVHR (grade II-III) positive skin explants (Figure 6C and 6D) in comparison to the medium 316 
control (p=0.02, p=0.02). 317 
 318 
 319 
 320 
 321 
 322 
 323 
 324 
 325 
 326 
 327 
 328 
 329 
 330 
 331 
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DISCUSSION 332 
Elevated BAFF levels have been previously reported in plasma of cGVHD patients (17, 23). Our 333 
results show sBAFF levels were already elevated pre-transplant in patients subsequently 334 
developing aGVHD indicating graft outcome may be influenced by transplant factors such as 335 
BAFF.  Decreased sBAFF levels at day 0 suggested an effect of the conditioning treatment on 336 
BAFF producing cells. Following conditioning a defect in cell mediated immunity occurs 337 
resulting in disruption of B cell homeostasis causing slow B cell reconstitution and impaired 338 
functionality (41). The sustained increase in BAFF levels observed in aGVHD patients following 339 
HSCT suggested delayed B cell recovery which may have contributed to loss of B cell tolerance 340 
and development of cGVHD (42). Elevated BAFF mRNA and protein expression confirmed its 341 
association with an increased risk of developing aGVHD. Moreover, increased sBAFF levels in 342 
cGVHD patients provided strong support for BAFF involvement in cGVHD with pre-transplant 343 
levels predicting aGVHD outcome. Therefore BAFF can be important for diagnosis or 344 
monitoring GVHD in response to acute and cGVHD therapy. Similarly the data for sIL-33 345 
suggests an important role for IL-33 in the development of aGVHD as recently reported (43).  346 
Chemokines have been implicated in the rejection of allogeneic transplants (44, 45). The CXCR3 347 
receptor and its ligands CXCL9/10/11 constitute an important pathway for effector cell 348 
recruitment post-transplant (19, 46). Increased CXCL10 levels in sera and aGVHD skin biopsies 349 
(18, 47) have been reported but no involvement in cGVHD. The increase in CXCL10/CXCL11 350 
levels in acute and cGVHD patient sera suggests a potential biomarker role for both chemokines 351 
and the perseverance of elevated CXCL10/CXCL11 levels during aGVHD may lead to 352 
development of cGVHD. Both CXCL10/CXCL11 where strongly influenced by the conditioning 353 
treatment received indicating conditioning induces early chemokine expression promoting T cell 354 
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migration into GVHD target organs and result in development of GVHD. Activation of 355 
chemokine expression using skin explant assays has recently been shown to induce T cell 356 
migration and IFNγ secretion exacerbating the graft versus host reaction (48). 357 
Interestingly, the biomarkers investigated work collectively downstream of each another in 358 
inflammatory response initiation. Inflammasome assembly at tissue damage sites results in 359 
caspase-1 release (49) and subsequent IL-33 activation (50) and binding to its receptor ST2 360 
(suppressor of tumorgenicity-2). This elicits danger signals recognized by immune cells which 361 
initiate an inflammatory response and express the CXCR3 receptor on the cell surface, resulting 362 
in CXCL10/CXCL11 binding and infiltration of effector T cells. ST2 itself has recently 363 
implicated as a biomarker for aGVHD (51) .    364 
In conclusion the training and validation cohort results highlight association of the investigated 365 
biomarkers to GVHD. Independent evaluation of the biomarkers in clinical biopsies and the skin 366 
explants strongly confirms association of each biomarker in predictive or diagnostic roles in 367 
acute or chronic GVHD. Our results show a combination of different markers can be used to 368 
predict both acute and cGVHD, however, use of a biomarker panel may be more effective to 369 
predict GVHD occurrence (52).  370 
 371 
 372 
 373 
 374 
Supplementary information is available at BMT's website 375 
19 
 
Acknowledgments 376 
The authors thank Elizabeth Douglas, Cindy Carr for technical support, Shelagh Lowerson for 377 
providing Clinical Data from Euro Bank and help with ROC analysis and Shazmeen Surtee for 378 
helping as part of her undergraduate project.  379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
20 
 
References 394 
1. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. 395 
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-396 
versus-host disease according to National Institutes of Health consensus criteria. Blood. 397 
2011;117(11):3214-9. 398 
2. Reddy P, Teshima T, Kukuruga M, Ordemann R, Liu C, Lowler K, et al. Interleukin-18 399 
regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. The 400 
Journal of experimental medicine. 2001;194(10):1433-40. 401 
3. Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S, et al. Donor CD4+ T and B 402 
cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. 403 
Blood. 2006;107(7):2993-3001. 404 
4. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324(10):667-74. 405 
5. Miura Y, Thoburn CJ, Bright EC, Chen W, Nakao S, Hess AD. Cytokine and chemokine 406 
profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma 407 
may be critical mediators for the development of autologous GVHD. Blood. 2002;100(7):2650-408 
8. 409 
6. Jaksch M, Remberger M, Mattsson J. Increased gene expression of chemokine receptors 410 
is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol 411 
Blood Marrow Transplant. 2005;11(4):280-7. 412 
7. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A 413 
biomarker panel for acute graft-versus-host disease. Blood. 2009;113(2):273-8. 414 
21 
 
8. Miyamoto T, Akashi K, Hayashi S, Gondo H, Murakawa M, Tanimoto K, et al. Serum 415 
concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. 416 
Bone marrow transplantation. 1996;17(2):185-90. 417 
9. Or R, Kalinkovich A, Nagler A, Weisman Z, Naparstek E, Weiss L, et al. Soluble tumor 418 
necrosis factor (sTNF) receptors: a possible prognostic marker for bone marrow transplantation-419 
related complications. Cytokines and molecular therapy. 1996;2(4):243-50. 420 
10. Imamura M, Hashino S, Kobayashi H, Kubayashi S, Hirano S, Minagawa T, et al. Serum 421 
cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, 422 
interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone marrow 423 
transplantation. 1994;13(6):745-51. 424 
11. Levine JE, Logan BR, Wu J, Alousi AM, Bolanos-Meade J, Ferrara JL, et al. Acute graft-425 
versus-host disease biomarkers measured during therapy can predict treatment outcomes: a 426 
Blood and Marrow Transplant Clinical Trials Network study. Blood.119(16):3854-60. 427 
12. Levine JE, Logan BR, Wu J, Alousi AM, Bolanos-Meade J, Ferrara JL, et al. Acute graft-428 
versus-host disease biomarkers measured during therapy can predict treatment outcomes: a 429 
Blood and Marrow Transplant Clinical Trials Network study. Blood 2012 Apr 19;119(16):3854-430 
60 Epub 2012 Mar 1. 2012. 431 
13. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, et al. A Prognostic Score 432 
for Acute Graft-Versus-Host Disease Based on Biomarkers: A Multicenter Study. The Lancet 433 
Haematology. 2015;2(1):e21-e9. 434 
14. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A Refined 435 
Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, 436 
Survival, and Transplant-Related Mortality. Biol Blood Marrow Transplant. 2015;21(4):761-7. 437 
22 
 
15. Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE, et al. Plasma 438 
biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012 Mar 22;119(12):2960-3 439 
Epub 2012 Jan 27. 2012. 440 
16. Shin OS, Harris JB. Innate immunity and transplantation tolerance: the potential role of 441 
TLRs/NLRs in GVHD. The Korean journal of hematology. 2011;46(2):69-79. 442 
17. Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, et al. High 443 
levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin 444 
Cancer Res. 2007;13(20):6107-14. 445 
18. Piper KP, Horlock C, Curnow SJ, Arrazi J, Nicholls S, Mahendra P, et al. CXCL10-446 
CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease 447 
in the skin following allogeneic stem-cell transplantation. Blood. 2007;110(12):3827-32. 448 
19. Croudace JE, Inman CF, Abbotts BE, Nagra S, Nunnick J, Mahendra P, et al. 449 
Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the 450 
pathogenesis of chronic GVHD. Blood. 2012;120(20):4246-55. 451 
20. Pavletic SZ, Carter SL, Kernan NA, Henslee-Downey J, Mendizabal AM, Papadopoulos 452 
E, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a 453 
multicenter randomized trial in unrelated marrow donor transplantation. Blood. 454 
2005;106(9):3308-13. 455 
21. Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. 456 
J Immunol. 2009;183(6):3561-7. 457 
22. Melchers F. Actions of BAFF in B cell maturation and its effects on the development of 458 
autoimmune disease. Annals of the rheumatic diseases. 2003;62 Suppl 2:ii25-7. 459 
23 
 
23. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, et al. 460 
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 461 
2009;113(16):3865-74. 462 
24. Nasti TH, Timares L. Inflammasome activation of IL-1 family mediators in response to 463 
cutaneous photodamage. Photochemistry and photobiology. 2012;88(5):1111-25. 464 
25. Landfried K, Bataille F, Rogler G, Brenmoehl J, Kosovac K, Wolff D, et al. Recipient 465 
NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. 466 
Clin Exp Immunol. 2009;159(1):87-92. 467 
26. Watson MJ, Ke B, Shen XD, Gao F, Busuttil RW, Kupiec-Weglinski JW, et al. Intestinal 468 
ischemia/reperfusion injury triggers activation of innate toll-like receptor 4 and adaptive 469 
chemokine programs. Transplant Proc. 2008;40(10):3339-41. 470 
27. Zeiser R, Penack O, Holler E, Idzko M. Danger signals activating innate immunity in 471 
graft-versus-host disease. J Mol Med (Berl). 2011;89(9):833-45. 472 
28. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821-32. 473 
29. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in 474 
immunity. Immunity. 2000;12(2):121-7. 475 
30. Dickinson AM, Sviland L, Carey P, Reid MM, Hamilton PJ, Pearson AJ, et al. Skin 476 
explant culture as a model for cutaneous graft-versus-host disease in humans. Bone Marrow 477 
Transplant. 1988;3(4):323-9. 478 
31. Vogelsang GB, Hess AD, Berkman AW, Tutschka PJ, Farmer ER, Converse PJ, et al. An 479 
in vitro predictive test for graft versus host disease in patients with genotypic HLA-identical 480 
bone marrow transplants. N Engl J Med. 1985;313(11):645-50. 481 
24 
 
32. Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, et al. Diagnosis and 482 
management of acute graft-versus-host disease. Br J Haematol. 2012;158(1):30-45. 483 
33. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National 484 
Institutes of Health consensus development project on criteria for clinical trials in chronic graft-485 
versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow 486 
Transplant. 2005;11(12):945-56. 487 
34. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) 488 
method. Nat Protoc. 2008;3(6):1101-8. 489 
35. Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, et al. 490 
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow 491 
transplantation. Blood. 1990;75(12):2459-64. 492 
36. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, et al. Chronic 493 
GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. 494 
Blood. 2011;117(24):6714-20. 495 
37. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, et al. B lymphocyte 496 
stimulator overexpression in patients with systemic lupus erythematosus: longitudinal 497 
observations. Arthritis and rheumatism. 2003;48(12):3475-86. 498 
38. Quartuccio L, Fabris M, Moretti M, Barone F, Bombardieri M, Rupolo M, et al. 499 
Resistance to Rituximab Therapy and Local BAFF Overexpression in Sjogren's Syndrome-500 
Related Myoepithelial Sialadenitis and Low-Grade Parotid B-Cell Lymphoma. The open 501 
rheumatology journal. 2008;2:38-43. 502 
25 
 
39. Mapara MY, Leng C, Kim YM, Bronson R, Lokshin A, Luster A, et al. Expression of 503 
chemokines in GVHD target organs is influenced by conditioning and genetic factors and 504 
amplified by GVHR. Biol Blood Marrow Transplant. 2006;12(6):623-34. 505 
40. Wang XN, Collin M, Sviland L, Marshall S, Jackson G, Schulz U, et al. Skin explant 506 
model of human graft-versus-host disease: prediction of clinical outcome and correlation with 507 
biological risk factors. Biol Blood Marrow Transplant. 2006;12(2):152-9. 508 
41. Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A. B cell reconstitution after 509 
human bone marrow transplantation: recapitulation of ontogeny? Bone marrow transplantation. 510 
1993;12(4):387-98. 511 
42. Brink R. Regulation of B cell self-tolerance by BAFF. Seminars in immunology. 512 
2006;18(5):276-83. 513 
43. Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, Liu Q, et al. The 514 
IL-33/ST2 axis augments effector T cell responses during acute GVHD. Blood. 2015. 515 
44. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, et al. Requirement of the 516 
chemokine receptor CXCR3 for acute allograft rejection. The Journal of experimental medicine. 517 
2000;192(10):1515-20. 518 
45. Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in 519 
allograft rejection. Current opinion in immunology. 2000;12(5):511-6. 520 
46. Uppaluri R, Sheehan KC, Wang L, Bui JD, Brotman JJ, Lu B, et al. Prolongation of 521 
cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal 522 
antibody. Transplantation. 2008;86(1):137-47. 523 
26 
 
47. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived 524 
IP-10 initiates development of acute allograft rejection. The Journal of experimental medicine. 525 
2001;193(8):975-80. 526 
48. Mavin E, Ahmed SS, O'Boyle G, Turner B, Douglass S, Norden J, et al. Regulatory T 527 
cells inhibit CD8(+) T-cell tissue invasion in human skin graft-versus-host reactions. 528 
Transplantation. 2012;94(5):456-64. 529 
49. Grenier JM, Wang L, Manji GA, Huang WJ, Al-Garawi A, Kelly R, et al. Functional 530 
screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB 531 
and caspase-1. FEBS Lett. 2002;530(1-3):73-8. 532 
50. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by 533 
caspase-1. Proc Natl Acad Sci U S A. 2009;106(22):9021-6. 534 
51. Ponce DM, Hilden P, Mumaw C, Devlin SM, Lubin M, Giralt S, et al. High day 28 ST2 535 
levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood 536 
transplantation. Blood. 2014. 537 
52. Levine JE, Logan BR, Wu J, Alousi AM, Bolanos-Meade J, Ferrara JL, et al. Acute graft-538 
versus-host disease biomarkers measured during therapy can predict treatment outcomes: a 539 
Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012;119(16):3854-60. 540 
  541 
 542 
 543 
 544 
 545 
27 
 
Figure Legends 546 
Figure 1.  sBAFF and sIL-33 levels in HSCT patient sera measured pre-transplant and at 547 
selected time-points post-transplant. Results are given for the training cohort (black bars) and 548 
validation cohort (grey bars) in HSCT patients with and without acute GVHD (left) and cGVHD 549 
(right). Graph shows mean sBAFF and sIL-33 levels (ng/ml) at each time-point tested. Results 550 
are shown for A; healthy individuals (Normal, in training cohort only n=8) and sBAFF levels in 551 
HSCT patients with and without acute GVHD.  B; sBAFF levels in HSCT patients with and 552 
without chronic GVHD. C; sIL-33 levels in HSCT patients with and without acute GVHD. D; 553 
sIL-33 levels in HSCT patients with and without chronic GVHD. P values indicated as *= 554 
p<0.01, **=p<0.001 and ***=p<0.0001  555 
 556 
Figure 2. sCXCL10 and sCXCL11 levels in HSCT patient sera measured pre-transplant 557 
and at different time-points post-transplant. . Results are given for the training cohort (black 558 
bars) and validation cohort (grey bars) in HSCT patients with and without acute GVHD (left) 559 
and cGVHD (right). Graph shows mean sCXCL10 and CXCL11 levels (pg/ml) at each time-560 
point tested. A; healthy individuals (Norm, in training cohort only) and sCXCL10 levels in 561 
HSCT patients with and without acute GVHD, B; sCXCL10 levels in HSCT patients with and 562 
without chronic GVHD. C; sCXCL10 levels in HSCT patients with and without chronic GVHD. 563 
D; sCXCL11 levels in HSCT patients with and without chronic GVHD. P values indicated as *= 564 
p<0.01, **=p<0.001 and ***=p<0.0001.  565 
 566 
Figure 3. Receiver Operating Characteristic (ROC) curve data for predicting aGVHD and 567 
cGVHD. A, The area under the curve (AUC), standard error (S.E.), P value and optimal cut-off 568 
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point is given for biomarkers which showed an AUC of 0.75 or above for acute or chronic 569 
GVHD patients. B, a representative image of ROC analysis of HSCT patients with chronic 570 
GVHD 12 months post-transplant.  571 
 572 
Figure 4. Cytokine/chemokine expression in in-vitro skin explants of HSCT patients. Box 573 
plots show the overall percentage of cells which stained positive for each cytokine/chemokine. 574 
A, BAFF expression was significantly (p=0.04) increased in GVHR positive skin explant assays 575 
(n=17 grade II-III GVHR) compared to GVHR negative skin explants (n=6, grade 0-I GVHR). 576 
B, IL-33 expression was significantly (p=0.004) increased in GVHR positive skin explant assays 577 
(n=19 grade II-III GVHR) compared to GVHR negative skin explants (n=7, grade 0-I GVHR) C, 578 
CXCL10 and D, CXCL11 expression was significantly increased (p=0.007 and p=0.01, 579 
respectively) in GVHR positive skin explant assays compared to GVHR negative skin explants. 580 
Representative immunohistochemistry images are given below each box plot showing expression 581 
in a GVHR negative skin explant and a GVHR positive skin explant for each 582 
cytokine/chemokine.  All images were acquired using a light microscope (Leitz Wetzer) at x 50 583 
magnification (1.32 OPL) and a digital camera (Canon, DS126071; Canon Utilities Browser EX 584 
software).  585 
 586 
Figure 5. Cytokine/chemokine expression in clinical biopsies of HSCT patients. 587 
Representative immunohistochemistry images of gastrointestinal tract biopsies of aGVHD 588 
patients (left) and HSCT patients with no acute GVHD (right). A, Membrane-bound staining of 589 
BAFF in a gut biopsy of an acute GVHD patient (left) and duodenum biopsy of HSCT patient 590 
with no acute GVHD (right). B, IL-33, C, CXCL10 and D, CXCL11 staining in a gut biopsy of 591 
29 
 
an acute GVHD patient (left) and of HSCT patient with no aGVHD right. All images were 592 
acquired using a light microscope (Leitz Wetzer) at x 50 magnification (1.32 OPL) and a digital 593 
camera (Canon, DS126071; Canon Utilities Browser EX software).  594 
 595 
Figure 6. CXCL10, CXCL11 and BAFF mRNA expression analysis in aGVHD clinical skin 596 
biopsies and in skin explant assays by RTPCR. 597 
Graphs show mRNA expression in either clinical skin biopsies from HSCT aGVHD patients in 598 
comparison to expression in normal healthy individuals or mRNA expression in skin explants 599 
compared to medium control (skin incubated in medium alone). The point 0 (dotted line) defines 600 
the expression of mRNA above or below this point.  A, CXCL10 and B, CXCL11 expression in 601 
acute GVHD clinical biopsies was significantly increased in comparison to normal skin (control) 602 
(p=0.001, p=0.0003). C, CXCL10 and D, CXCL11  expression in GVHR grade III skin explants 603 
was significantly increased when compared to medium control (p=0.02, p=0.02) (Mann Whitney 604 
U test). E, Quantitative RT-qPCR analysis of BAFF mRNA expression in acute GVHD clinical 605 
skin biopsies. Results are given relative to GAPDH and BAFF expression in pre-HSCT biopsies. 606 
BAFF expression was significantly higher in grades II-III acute GVHD patient biopsies in 607 
comparison to grades 0-I aGVHD. Mann-Whitney U test was used to determine significance.  608 
Table 1. Patients Characteristics for BAFF, IL-33, CXCL10 and CXCL11 protein and 
mRNA expression in patient sera, skin explant assays and clinical biopsies. 
 
Characteristic P 
value 
n (%) 
     Cohort  NCL 
(training 
cohort) 
Rgn (validation 
cohort) 
 0.000   78 (100) 37(100) 
Sex    
Male recipients 0.000 49 (63) 25 (68) 
Female recipients 0.001 29 (37) 12 (32) 
Female donor to Male 0.000 20 (26)   7 (37) 
     
Type of transplant    
Myeloablative 0.02 24 (30)  4 (11) 
Reduced Intensity Cond. (RIC) 0.000 54 (69) 33 (89) 
     
Steroid treatment after HSCT  20 (25) 23 (62) 
    
Donor type    
HLA-identical sibling 0.000 39 (50) 33 (89) 
HLA-matched unrelated 0.01 39 (50)   4 (11) 
     
Acute GVHD  56 (72) 22 (59) 
Grade 0-I  23 (29) 12 (32) 
Grade II  23 (29)   6 (16) 
GradeIII>  10 (13)   4 (11) 
     
Chronic GVHD  42 (53) 14 (38) 
     
Diagnosis    
Acute myeloid leukemia  26 (33) 17 (47) 
Acute lymphoblastic leukemia    9 (12)  2 (5) 
Chronic myelogenous leukemia   6 (8)  2 (5) 
Myledysplastic syndrome  10 (13)  3 (8) 
Aplastic anemia  2 (3)  
Hodgkins lymphoma  5 (6)  1 (3) 
Non-Hodgkins lymphoma  16 (21)  2 (5) 
Plasma cell neoplasm  2 (3)  3 (8) 
Other   1 (1)   7 (19) 
 
Table 2. Data showing BAFF, IL-33, CXCL10 and CXCL11 levels at different time points in 
aGVHD or cGVHD patients compared to control groups.  Only time points displaying a 
significant change in levels in the training cohort or validation cohort or in both are listed.  
Acute GVHD    
Biomarker Cohort 
 
Cohort 
total (n=) 
Test  group 
aGVHD(n=) 
Control 
group -no 
aGVHD (n=) 
Time point Significant 
increase p 
value 
Significant 
decrease p 
value 
BAFF Training 22 15 7 Pretransplant 0.0002 
BAFF Validation 25 17 8 Pr-transplant 0.0001 
BAFF Training 22 15 7 Day 14 0.03 
BAFF Validation 25 17 8 Day 14 0.049 
IL-33 Training 21 13 8 Day 0 0.03 
IL-33 Validation 21 14 7 Day 28 0.03 
IL-33 Training 21 14 7 Day 28 0.045 
CXCL10 Training 54 33 21 Pretransplant 0.01 
CXCL10 Training 54 33 21 Day 0  0.03
CXCL10 Training 54 33 21 Day 14 0.0001 
CXCL10 Validation 36 21 15 Day 14 0.02 
CXCL10 Training 54 33 21 Day 28 0.0001 
CXCL10 Validation 36 21 15 Day 28 0.03 
CXCL11 Training 54 33 21 Day 14 0.001 
CXCL11 Validation 36 21 15 Day 14 0.02 
CXCL11 Training 54 33 21 Day 28 0.007 
CXCL11 Validation 36 21 15 Day 28 0.03 
Chronic 
GVHD 
   
Biomarker Cohort 
  
Cohort 
total (n=) 
Test  group-
cGVHD(n=) 
Control 
group -no 
cGVHD (n=) 
Time point Significant 
increase  p 
value 
Significant 
decrease p 
value 
BAFF Training 28 18 10 12 months 0.002 
BAFF Validation 22 8 14 12 months 0.03 
BAFF Validation 22 8 14 6 months 0.02 
IL-33 Training 18 8 10 3 months 0.03 
IL-33 Validation 19 13 6 3 months  0.04
CXCL10 Training 44 22 22 3 months 0.02 
CXCL10 Training 44 22 22 6 months 0.02 
CXCL10 Validation 37 28 9 6 months 0.03 
CXCL10 Training 44 22 22 12 months 0.0001 
CXCL10 Validation 37 28 9 12 months 0.03 
CXCL11 Validation 37 28 9 3 Months 0.03 
CXCL11 Training 44 22 22 6 months 0.02 
CXCL11 Validation 37 28 9 6 months 0.01 
CXCL11 Training 44 22 22 12 months 0.01 
CXCL11 Validation 37 28 9 12 months 0.02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 






